THURSDAY, Feb. 20, 2025 — For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients receiving standard of care (SOC), according to a…Original Article
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
THURSDAY, Feb. 20, 2025 — For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients receiving standard of care (SOC), according to a…
